Navigation Links
Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
Date:1/23/2013

ITHACA, N.Y. With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread. (PLOS ONE, Jan. 23, 2013)

Pro-inflammatory signaling molecules in blood called cytokines constitute a "switch" that induces the mechanism by which breast cancer cells "roll" and adhere to the blood vessel surface. The cancer cells eventually stick to the vessel and infiltrate it.

The laboratory of Michael R. King, Cornell professor of biomedical engineering has developed a flow chamber that mimics an inflamed endothelium (the blood vessel wall) and has used this to investigate the metastatic cascade.

In understanding the adhesive behavior of a particularly metastatic cell line, King and Yue Geng, graduate student in the field of biomedical engineering, discovered unexpectedly that these cells were unable to interact with selectins (receptor sites on the endothelium) a key step in the metastatic cascade. This mechanism is identical to how white blood cells infiltrate blood vessels to reach the site of inflammation.

Cancer has long been associated with inflammation the body's natural defense mechanism and now the researchers have demonstrated a definitive link. They found that the presence of pro-inflammatory molecules the cytokines IL-6 and TNF-alpha enable the malignant, hormone therapy-resistant breast cancer cells used in the study to adhere to the endothelial wall, leading to metastasis.

Before the cancer has spread, tumor cells first encounter IL-6 and TNF-alpha in the primary tumor's microenvironment. These cytokines induce proliferation and aggregation of cancer cells, triggering other cancer cells to secrete more cytokines, resulting in a positive feedback loop.

The bioengineers went on to design several different cell culture setups to culture cancer cells with human plasma, IL-6 and TNF-alpha to test their hypotheses that inflammatory molecules in blood may induce adhesion capability. All of them promoted breast cancer cell metastatic behavior.

To confirm the results, the scientists used more sophisticated, real-life 3-D tumor spheroids, which are more physiologically accurate. In fact, the spheroid tumor cells exhibited the most significant increase in the interaction between the cancer cells and the blood vessel. They also treated some of the samples with a known anti-inflammatory drug called Metformin, which blocks IL-6, and they found that these samples were not able to metastasize further accentuating their results.

Improving cancer treatment to fight metastasis via the bloodstream will depend on undoing this roll-and-stick mechanism of cancer cells, Geng says. The Cornell research could form the basis for immunotherapies to block the ligand-selectin binding of cancer cells, by first counteracting the inflammatory cytokines that, it seems, set the whole process in motion.


'/>"/>

Contact: John Carberry
jjc338@cornell.edu
607-255-5353
Cornell University
Source:Eurekalert

Related biology technology :

1. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
2. Rice University discovers that graphene oxide soaks up radioactive waste
3. New Way to Kill Bed Bugs Discovered; Bed Bug Bully Says Use of Bed Bug Spray Remains the Better Technique to Kill the Pests
4. MIT researchers discover a new kind of magnetism
5. Automated design for drug discovery
6. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
7. Research discovery could revolutionize semiconductor manufacture
8. Stem Cell Pioneer Recognized for 20 Years of Discovery and Innovation
9. Discovery could hold the key to super-sensory hearing
10. Sweet diesel! Discovery resurrects process to convert sugar directly to diesel
11. New discovery shows promise in future speed of synthesizing high-demand nanomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):